TC
TCMFF
TELECOM ARGENTINA SA
$2.10
0.00%
No data for this timeframe.
Vol
SEC Reports3
Recent Activity
May 11, 2026
SEC
Telecom Argentina reported Q1 2026 results with consolidated revenues of P$2,357,686 million (+33.6% YoY) and net income
6-K — Impact 5/10
Apr 30, 2026
SEC
Telecom Argentina disclosed an extension of the antitrust review period for a pending transaction. The Argentine Antitru
6-K — Impact 3/10
Apr 15, 2026
SEC
Telecom Argentina SA announced a preliminary merger agreement to absorb its wholly-owned subsidiary Teledifusora San Mig
6-K — Impact 4/10
Analyst Ratings
0Strong Buy
0Buy
2Hold
2Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 11, 2018 | JP Morgan | MAINTAIN | Neutral → Neutral |
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 4.0/10.
MIXED
6-K
5/10
Telecom Argentina reported Q1 2026 results with consolidated revenues of P$2,357,686 million (+33.6%
May 11, 2026
NEUTRAL
6-K
3/10
Telecom Argentina disclosed an extension of the antitrust review period for a pending transaction. T
Apr 30, 2026
NEUTRAL
6-K
4/10
Telecom Argentina SA announced a preliminary merger agreement to absorb its wholly-owned subsidiary
Apr 15, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Apr 2018): 0% buy across 6 analysts — 0 strong buy, 0 buy, 2 hold, 2 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $2.5B | 66.7% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $2.0B | 36.9% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $6.5B | 10.0% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $7.6B | 16.6% | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 11, 2018 | JP Morgan | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | 0 | 0 | 2 | 2 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 2 | 2 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 2 | 2 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 2 | 2 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.